2,000,000 Shares in Abeona Therapeutics Inc. $ABEO Purchased by AIGH Capital Management LLC

Key Points

• AIGH Capital Management purchased 2,000,000 shares of Abeona (≈$10.54M) in Q4, representing about 3.69% ownership of the company and making ABEO roughly 2.6% of AIGH's holdings (its 14th largest position).
• Sell‑side coverage is largely positive: four analysts rate ABEO a Buy versus one Sell, with a consensus rating of "Moderate Buy" and a consensus target price of $19.00, while the stock trades near $5.43 and has a market cap of about $309M.
• Institutional investors own about 80.56% of the stock, but insiders have sold shares recently—56,419 shares worth ~$287k over the last 90 days—leaving insiders with roughly 6.9% ownership.

AIGH Capital Management LLC purchased a new position in Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 2,000,000 shares of the biopharmaceutical company's stock, valued at approximately $10,540,000. Abeona Therapeutics accounts for about 2.6% of AIGH Capital Management LLC's holdings, making the stock its 14th largest holding. AIGH Capital Management LLC owned 3.69% of Abeona Therapeutics as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. Legal & General Group Plc purchased a new position in Abeona Therapeutics during the 2nd quarter valued at about $27,000. Russell Investments Group Ltd. purchased a new position in Abeona Therapeutics during the 3rd quarter valued at about $37,000. SG Americas Securities LLC purchased a new position in Abeona Therapeutics during the 4th quarter valued at about $57,000. Legato Capital Management LLC purchased a new position in shares of Abeona Therapeutics in the 3rd quarter worth approximately $57,000. Finally, Man Group plc purchased a new position in shares of Abeona Therapeutics in the 2nd quarter worth approximately $67,000. Hedge funds and other institutional investors own 80.56% of the company's stock.

Abeona Therapeutics Trading Down 0.5%

Shares of ABEO opened at $5.43 on Friday. The company has a current ratio of 6.93, a quick ratio of 6.74 and a debt-to-equity ratio of 0.05. Abeona Therapeutics Inc. has a 12-month low of $4.00 and a 12-month high of $7.54. The firm has a 50-day moving average price of $4.98 and a 200 day moving average price of $5.03. The firm has a market capitalization of $308.86 million, a P/E ratio of 5.27 and a beta of 1.35.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its quarterly earnings data on Tuesday, March 17th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.01. The firm had revenue of $3.00 million during the quarter, compared to analysts' expectations of $5.65 million. Sell-side analysts forecast that Abeona Therapeutics Inc. will post -0.6 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently commented on ABEO shares. Stifel Nicolaus set a $17.00 price objective on Abeona Therapeutics in a report on Tuesday, March 17th. Oppenheimer reissued an "outperform" rating on shares of Abeona Therapeutics in a research report on Monday, March 9th. HC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of Abeona Therapeutics in a research report on Thursday, March 19th. Finally, Weiss Ratings reissued a "sell (d+)" rating on shares of Abeona Therapeutics in a research report on Wednesday, January 21st. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $19.00.

Insiders Place Their Bets

In other Abeona Therapeutics news, Director Eric Crombez sold 16,284 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $5.09, for a total transaction of $82,885.56. Following the completion of the transaction, the director owned 63,456 shares of the company's stock, valued at $322,991.04. This trade represents a 20.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Leila Alland sold 18,065 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $5.09, for a total transaction of $91,950.85. Following the transaction, the director directly owned 173,614 shares of the company's stock, valued at approximately $883,695.26. This trade represents a 9.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 56,419 shares of company stock valued at $287,173 over the last 90 days. 6.90% of the stock is owned by company insiders.

Abeona Therapeutics Profile

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company's research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company's lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.